Pharmacomechanical Catheter‐Directed Thrombolysis for Deep‐Vein Thrombosis

Background The post‐thrombotic syndrome frequently develops in patients with proximal deep‐vein thrombosis despite treatment with anticoagulant therapy. Pharmacomechanical catheter‐directed thrombolysis (hereafter “pharmacomechanical thrombolysis”) rapidly removes thrombus and is hypothesized to reduce the risk of the post‐thrombotic syndrome. Methods We randomly assigned 692 patients with acute proximal deep‐vein thrombosis to receive either anticoagulation alone (control group) or anticoagulation plus pharmacomechanical thrombolysis (catheter‐mediated or device‐mediated intrathrombus delivery of recombinant tissue plasminogen activator and thrombus aspiration or maceration, with or without stenting). The primary outcome was development of the post‐thrombotic syndrome between 6 and 24 months of follow‐up. Results Between 6 and 24 months, there was no significant between‐group difference in the percentage of patients with the post‐thrombotic syndrome (47% in the pharmacomechanical‐thrombolysis group and 48% in the control group; risk ratio, 0.96; 95% confidence interval [CI], 0.82 to 1.11; P=0.56). Pharmacomechanical thrombolysis led to more major bleeding events within 10 days (1.7% vs. 0.3% of patients, P=0.049), but no significant difference in recurrent venous thromboembolism was seen over the 24‐month follow‐up period (12% in the pharmacomechanical‐thrombolysis group and 8% in the control group, P=0.09). Moderate‐to‐severe post‐thrombotic syndrome occurred in 18% of patients in the pharmacomechanical‐thrombolysis group versus 24% of those in the control group (risk ratio, 0.73; 95% CI, 0.54 to 0.98; P=0.04). Severity scores for the post‐thrombotic syndrome were lower in the pharmacomechanical‐thrombolysis group than in the control group at 6, 12, 18, and 24 months of follow‐up (P<0.01 for the comparison of the Villalta scores at each time point), but the improvement in quality of life from baseline to 24 months did not differ significantly between the treatment groups. Conclusions Among patients with acute proximal deep‐vein thrombosis, the addition of pharmacomechanical catheter‐directed thrombolysis to anticoagulation did not result in a lower risk of the post‐thrombotic syndrome but did result in a higher risk of major bleeding. (Funded by the National Heart, Lung, and Blood Institute and others; ATTRACT ClinicalTrials.gov number, NCT00790335.)

[1]  L. Sandvik,et al.  Post-thrombotic syndrome after catheter-directed thrombolysis for deep vein thrombosis (CaVenT): 5-year follow-up results of an open-label, randomised controlled trial. , 2016, The Lancet. Haematology.

[2]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[3]  L. Robertson,et al.  Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosis. , 2015, The Cochrane database of systematic reviews.

[4]  Chad J Zack,et al.  Comparative outcomes of catheter-directed thrombolysis plus anticoagulation vs anticoagulation alone to treat lower-extremity proximal deep vein thrombosis. , 2014, JAMA internal medicine.

[5]  S. Kahn,et al.  Compression Stockings to Prevent Post-Thrombotic Ayndrome: A Randomised Placebo-Controlled Trial , 2014 .

[6]  S. Goldhaber,et al.  Rationale and design of the ATTRACT Study: a multicenter randomized trial to evaluate pharmacomechanical catheter-directed thrombolysis for the prevention of postthrombotic syndrome in patients with proximal deep vein thrombosis. , 2013, American heart journal.

[7]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[8]  L. Sandvik,et al.  Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial , 2012, The Lancet.

[9]  W. Marston,et al.  Revision of the venous clinical severity score: venous outcomes consensus statement: special communication of the American Venous Forum Ad Hoc Outcomes Working Group. , 2010, Journal of vascular surgery.

[10]  D Bergqvist,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients , 2010, Journal of thrombosis and haemostasis : JTH.

[11]  S. Kahn.  Measurement properties of the Villalta scale to define and classify the severity of the post‐thrombotic syndrome , 2009, Journal of thrombosis and haemostasis : JTH.

[12]  P. Prandoni,et al.  Definition of post‐thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization , 2009, Journal of thrombosis and haemostasis : JTH.

[13]  G. Moneta.  Determinants and Time Course of the Postthrombotic Syndrome after Acute Deep Venous Thrombosis , 2009 .

[14]  D. Lamping,et al.  Determinants of health‐related quality of life during the 2 years following deep vein thrombosis , 2008, Journal of thrombosis and haemostasis : JTH.

[15]  M. Razavi,et al.  Clinical and economic evaluation of the Trellis-8 infusion catheter for deep vein thrombosis. , 2008, Journal of vascular and interventional radiology : JVIR.

[16]  G. Guyatt,et al.  Physicians Evidence-Based Clinical Practice Development : American College of Chest Thrombolytic Therapy Guideline Methodology for Antithrombotic and , 2008 .

[17]  R. Baum,et al.  A new method for aggressive management of deep vein thrombosis: retrospective study of the power pulse technique. , 2006, Journal of vascular and interventional radiology : JVIR.

[18]  Marc S. Schwartzberg,et al.  Reporting standards for endovascular treatment of lower extremity deep vein thrombosis. , 2006, Journal of vascular and interventional radiology : JVIR.

[19]  Donald L. Miller,et al.  Quality improvement guidelines for the treatment of lower extremity deep vein thrombosis with use of endovascular thrombus removal. , 2006, Journal of vascular and interventional radiology : JVIR.

[20]  P. Bijur,et al.  Relationship between intensity and relief in patients with acute severe pain. , 2005, The American journal of emergency medicine.

[21]  M. Prins,et al.  Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome , 2005, Journal of thrombosis and haemostasis : JTH.

[22]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.

[23]  M. Prins,et al.  Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: A randomized, controlled trial , 2005 .

[24]  B. Rubin,et al.  Pharmacomechanical thrombolysis and early stent placement for iliofemoral deep vein thrombosis. , 2004, Journal of vascular and interventional radiology : JVIR.

[25]  A. Mansfield,et al.  Venous Claudication in Iliofemoral Thrombosis: Long-term Effects on Venous Hemodynamics, Clinical Status, and Quality of Life , 2004 .

[26]  S. Schroter,et al.  Evaluation of outcomes in chronic venous disorders of the leg: development of a scientifically rigorous, patient-reported measure of symptoms and quality of life. , 2003, Journal of vascular surgery.

[27]  A. AbuRahma,et al.  Iliofemoral Deep Vein Thrombosis: Conventional Therapy Versus Lysis and Percutaneous Transluminal Angioplasty and Stenting , 2001, Annals of surgery.

[28]  G. Seabrook,et al.  Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. , 1999, Radiology.

[29]  H. Büller,et al.  Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis , 1997, The Lancet.

[30]  Paolo Prandoni,et al.  The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[31]  S. Shoab,et al.  Thrombolysis for acute deep vein thrombosis. , 1996, The British journal of surgery.

[32]  M. Dake,et al.  Iliofemoral deep venous thrombosis: aggressive therapy with catheter-directed thrombolysis. , 1994, Radiology.

[33]  P. Ohlin,et al.  Long-term results of venous thrombectomy combined with a temporary arterio-venous fistula. , 1990, European journal of vascular surgery.

[34]  M. Gent,et al.  Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis. Results of a randomized trial. , 1990, Chest.

[35]  A. Høiseth,et al.  Streptokinase of heparin in the treatment of deep vein thrombosis. Follow-up results of a prospective study. , 2009, Acta medica Scandinavica.

[36]  S. Benatar,et al.  A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: An interim report of a prospective trial , 1979, The British journal of surgery.

[37]  V. Marder,et al.  Quantitative venographic assessment of deep vein thrombosis in the evaluation of streptokinase and heparin therapy. , 1977, The Journal of laboratory and clinical medicine.